In re: EpiPen Direct Purchaser Litigation

District Court, D. Minnesota·Decided April 10, 2023·No. 0:20-cv-00827·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

In re: EpiPen Direct Purchaser Litigation File No. 20-cv-0827 (ECT/JFD)

THIS DOCUMENT RELATES TO: OPINION AND ORDER ALL ACTIONS ________________________________________________________________________ Noah Silverman, Bruce E. Gerstein, Jonathan M. Gerstein, Samuel E. Bonderoff, and Joseph Opper, Garwin Gerstein & Fisher LLP, New York, NY; David F. Sorenson, Caitlin G. Coslett, and Andrew C. Curley, Berger Montague PC, Philadelphia, PA; E. Michelle Drake, Berger & Montague PC, Minneapolis, MN; David S. Golub and Steven Bloch, Silver Golub & Teitell LLP, Stamford, CT; Susan C. Segura, David C. Raphael, Jr., and Erin R. Leger, Smith Segura & Raphael, LLP, Alexandria, LA; Russell Chorush, Christopher M. First, and Eric Enger, Heim Payne & Chorush LLP, Houston, TX; Joseph T. Lukens and Peter Kohn, Faruqi & Faruqi, LLP, Philadelphia, PA; Stuart Des Roches, Andrew Kelly, Amanda Leah Hass, Chris Letter, Dan Chiorean, and Thomas Maas, Odom & Des Roches, LLC, New Orleans, LA, for Plaintiffs Rochester Drug Co-Operative, Inc., and Dakota Drug, Inc.

Adam K. Levin, Carolyn A. DeLone, Christine A. Sifferman, Christopher Fitzpatrick, Devin Urness, Elizabeth Jose, Justin Bernick, Charles A. Loughlin, David M. Foster, and Michael D. Gendall, Hogan Lovells US LLP, Washington, DC; Peter H. Walsh and Anthony Ufkin, Hogan Lovells US LLP, Minneapolis, MN; Brittany C. Armour, Hogan Lovells US LLP, Philadelphia, PA; Katherine Booth Wellington, Hogan Lovells US LLP, Boston, MA; and Brian C. Fries, Carrie E. Josserand, Lathrop GPM LLP, Kansas City, MO; and Jason Johnson, Lathrop GPM LLP, Minneapolis, MN, for Defendants Mylan Inc. and Mylan Specialty L.P.

Craig D. Singer, Daniel M. Dockery, Enu A. Mainigi, David Bassali, Dylan McDevitt, Lori Jo Interlicchio, McKayla Stokes, Raymond Kennon Poteat III, Annie Showalter, Ashley Wall Hardin, and Atticus DeProspo, Williams & Connolly LLP, Washington, DC, and John W. Ursu and Isaac B. Hall, Faegre Drinker Biddle & Reath LLP, Minneapolis, MN, for Defendants Caremark PCS Health LLC, Caremark LLC, Caremark Rx LLC, and CVS Caremark Part D Services, LLC.

Donald G. Heeman, Jessica J. Nelson, and Randi J. Winter, Spencer Fane LLP, Minneapolis, MN; Jonathan Gordon Cooper, Michael John Lyle, Eric Christopher Lyttle, and Samuel Johnson, Nicholas Inns, Michael Benjamin Soyfer, Michael Chesley Smith, Quinn Emanuel Urquhart & Sullivan LLP, Washington, DC, and Ellison Ward Merkel, Quinn Emanuel Urquhart & Sullivan LLP, New York, NY, for Defendants Express Scripts Inc. and Medco Health Solutions Inc.

Kadee Jo Anderson and Andrew Glasnovich, Stinson LLP, Minneapolis, MN; Elizabeth Broadway Brown, David Andrew Hatchett, Bradley Harder, and Jordan Elise Edwards, Alston & Bird LLP, Atlanta, GA; Brian David Boone and Brandon C.E. Springer, Alston & Bird LLP, Charlotte, NC, for Defendants OptumRX Inc. and United Healthcare, Inc. ________________________________________________________________________ Plaintiffs Rochester Drug Co-Operative, Inc., and Dakota Drug, Inc., are drug wholesalers. On behalf of a proposed class, Plaintiffs claim that Defendants Mylan Inc. and Mylan Specialty L.P. (collectively, “Mylan”), the manufacturers of a device called the “EpiPen,”1 paid bribes and kickbacks to a group of pharmacy benefit managers (the “PBM Defendants”) 2 to ensure that Mylan could raise the price of the EpiPen with impunity while also keeping a monopoly share of the market. In doing so, Plaintiffs claim, all Defendants violated the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1962(c), and Mylan violated the Sherman Antitrust Act, 15 U.S.C. § 2.

1 The term “EpiPen” refers collectively to a group of Mylan products that encompasses the EpiPen, EpiPen Jr., EpiPen 2-Pak, and EpiPen Jr. 2-Pak. See First Amended and Consolidated Class Action Complaint (“1st Am. Compl.”) [ECF No. 271] ¶ 1. Auto-injector devices “allow a patient to quickly self-administer a prescribed amount of the drug epinephrine through a spring-loaded needle.” Id. ¶¶ 2, 42–43. Epinephrine auto-injectors like the EpiPen are used as “an emergency treatment for severe allergic reactions.” Id.

2 The PBM Defendants are: CaremarkPCS Health, L.L.C., Caremark, L.L.C., Caremark Part D Services, L.L.C., Caremark Rx, L.L.C., Express Scripts, Inc., Medco Health Solutions, Inc., and Optum Rx, Inc. The case’s docket also identifies United Healthcare, Inc. as an active party, but this is a mistake. United Healthcare, Inc. was dismissed. Opinion and Order [ECF No. 414] at 4 n.4, 23–28. The Clerk will be directed to correct the docket to reflect that United Healthcare, Inc. is no longer a party. 2 Defendants seek partial judgment on the pleadings under Federal Rule of Civil Procedure 12(c) with respect to Plaintiffs’ RICO (Count I) and RICO conspiracy (Count II) claims. Specifically, Defendants seek judgment to the extent these claims rely on statutes of California, Rhode Island, New Jersey, Missouri, Pennsylvania, Illinois, Virginia, and Texas as direct RICO predicate acts or as RICO predicate acts under the Travel Act. Defendants’ motion will be granted in part and denied in part. Plaintiffs cannot plausibly allege a RICO predicate act under California Penal Code § 641.3 because the

statute does not reach conduct by business organizations. Plaintiffs have not plausibly pleaded a valid RICO predicate act under Texas Penal Code § 32.43 as to Defendant OptumRx because Plaintiffs do not allege facts plausibly showing that OptumRx engaged in any Texas-based conduct. Defendants’ motion will be denied in all other respects. I

A motion for judgment on the pleadings under Rule 12(c) is assessed under the same standard as a motion to dismiss under Rule 12(b)(6). Ashley Cnty. v. Pfizer, Inc., 552 F.3d 659, 665 (8th Cir. 2009). In reviewing a motion to dismiss for failure to state a claim under Rule 12(b)(6), a court must accept as true all of the factual allegations in the complaint and draw all reasonable inferences in the plaintiff's favor. Gorog v. Best Buy Co., 760 F.3d

787, 792 (8th Cir. 2014) (citation omitted). Although the factual allegations need not be detailed, they must be sufficient to “raise a right to relief above the speculative level.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (citation omitted). The complaint must “state a claim to relief that is plausible on its face.” Id. at 570. “A claim has facial

3 plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). This is Defendants’ third Rule 12 motion.3 Though Plaintiffs criticize Defendants for taking “a third bite at the apple,” Pls.’ Mem. in Opp’n [ECF No. 643] at 8,4 Plaintiffs identify no legal rule that might make Defendants’ motion improper, and the motion seems procedurally proper and an apt fit for Defendants’ purely legal arguments. Rule 12(c) says

that “a party may move for judgment on the pleadings” “[a]fter the pleadings are closed— but early enough not to delay trial.” Fed. R. Civ. P. 12(c).

Free access — add to your briefcase to read the full text and ask questions with AI

In re: EpiPen Direct Purchaser Litigation, (mnd 2023).

In re: EpiPen Direct Purchaser Litigation (In re: EpiPen Direct Purchaser Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Republic of Panama v. BCCI Holdings (Luxembourg) S.A.
119 F.3d 935 (Eleventh Circuit, 1997)
Beck v. Prupis
529 U.S. 494 (Supreme Court, 2000)
Cook County v. United States Ex Rel. Chandler
538 U.S. 119 (Supreme Court, 2003)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Crest Construction II, Inc. v. Doe
660 F.3d 346 (Eighth Circuit, 2011)
Law v. Commonwealth
571 S.E.2d 893 (Court of Appeals of Virginia, 2002)
Nitro Distributing, Inc. v. Alticor, Inc.
565 F.3d 417 (Eighth Circuit, 2009)
Ashley County, Ark. v. Pfizer, Inc.
552 F.3d 659 (Eighth Circuit, 2009)
In Re Advisory Opinion to the House of Representatives
576 A.2d 1371 (Supreme Court of Rhode Island, 1990)
United States v. Johns
742 F. Supp. 196 (E.D. Pennsylvania, 1990)
McGowan v. State
938 S.W.2d 732 (Court of Appeals of Texas, 1997)
Jaclyn, Inc. v. Edison Brothers Stores, Inc.
406 A.2d 474 (New Jersey Superior Court App Division, 1979)
Weightman v. State
975 S.W.2d 621 (Court of Criminal Appeals of Texas, 1998)
Christopher Gorog v. Best Buy Co., Inc.
760 F.3d 787 (Eighth Circuit, 2014)
People v. Riley
240 Cal. App. 4th 1152 (California Court of Appeal, 2015)
Anand Munsif v. Christine Cassel
331 F. App'x 954 (Third Circuit, 2009)
Barone Lumber Co., Inc. v. Sowden
153 A. 308 (Supreme Court of Rhode Island, 1931)